The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients
(
1111 Hall PS, Harshman LC, Srinivas S, Witteles RM. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC: Heart Fail[Internet]. 2013 [cited 2016 Oct 16]; 1(1):72-8. Available from: http://www.sciencedirect.com/science/article/pii/S2213177912000030
http://www.sciencedirect.com/science/art...
)
|
United States/ 2013 |
Cohort 289 patients with advanced renal cell carcinoma |
- Sunitinib: heart failure (2%), coronary artery disease (9%) and atrial fibrillation (1%). - Sorafenib: heart failure (4%), coronary artery disease (5%) and atrial fibrillation (4%). - Pazopanib: heart failure (2%), coronary artery disease (2%) and atrial fibrillation (5%). |
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma
(
1212 Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol [Internet]. 2008 [cited 2016 Oct 16]; 26(32):5204-12. Available from: http://jco.ascopubs.org/content/26/32/5204.full.pdf+html
http://jco.ascopubs.org/content/26/32/52...
)
|
United States, 2008 |
Cohort 86 patients with metastatic renal cell carcinoma |
- Sunitinib or sorafenib: changes in electrocardiogram (46.5%), reduced left ventricular ejection fraction (10.4%); pericardial effusion (1%), rise in cardiac enzymes (30%). |
Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study
(
1313 DuBois SG, Shusterman S, Ingle AM, Ahern CH, Reid JM, Wu B, et al. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clin Cancer Res [Internet]. 2011 [cited 2016 Oct 16]; 17(15):5113-22. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149978/pdf/nihms303199.pdf
https://www.ncbi.nlm.nih.gov/pmc/article...
)
|
United States, 2010 |
Clinical trial 33 patients from 2 to 21 years old with refractory solid tumors |
- Sunitinib: Left ventricular systolic dysfunction (8.6%), prolongation of QTc on the electrocardiogram (8.6%). |
Hyperlipidemia and Hypothyroidism Among Metastatic Renal Cell Carcinoma Patients Taking Sunitinib Malate
(
1414 Tassi R, Baldazzi V, Lapini A, Carini M, Mazzanti R. Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate: related or unrelated adverse events? Clin Genitour Cancer[Internet]. 2015 [cited 2016 Oct 16]; 13(2):e101-5. Available from: http://www.clinical-genitourinary-cancer.com/article/S1558-7673(14)00202-X/pdf
http://www.clinical-genitourinary-cancer...
)
|
United States, 2015 |
Cohort 39 patients with metastatic renal cell carcinoma |
- Sunitinib: decrease of left ventricular function and death after myocardial infarction (2.5%). |
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
(
1515 Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixie O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med [Internet]. 2007 [cited 2016 Oct 16]; 356:115-24. Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa065044
http://www.nejm.org/doi/pdf/10.1056/NEJM...
)
|
United States, 2007 |
Clinical trial 750 patients with metastatic renal cell carcinoma |
- Sunitinib: reduced left ventricular ejection fraction (2%).- Interferon alfa: decrease of left ventricular ejection fraction (1%). |
Rare Incidence of Congestive Heart Failure in Gastrointestinal Stromal Tumor and Other Sarcoma Patients Receiving Imatinib Mesylate (IM)
(
1616 Trent JC, Patel SS, Zhang J, Araujo DM, Plana J, Lenihan DJ, et al. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving Imatinib Mesylate (IM). Cancer [Internet]. 2010 [cited 2016 Oct 16]; 116(1):184-92. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306337/pdf/nihms149947.pdf
https://www.ncbi.nlm.nih.gov/pmc/article...
)
|
United States, 2010 |
Cohort 219 patients with sarcoma |
- Imatinibe: myocardial ischemia or chest pain (2.3%), arrhythmias (0.9%); alterations in the electrocardiogram (1%), left ventricular dysfunction (0.4%), cardiac arrest (0.4%), heart failure (0.5%). |
Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer
(
1717 Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer. J Clin Oncol [Internet]. 2010 [cited 2016 Oct 16]; 28:1124-30. Available from: http://jco.ascopubs.org/content/28/7/1124.full.pdf+html
http://jco.ascopubs.org/content/28/7/112...
)
|
United States, 2010 |
Clinical trial 296 women with ErbB2-positive metastatic breast cancer |
- Lapatinib: reduced left ventricular ejection fraction (2%). |
Phase 1 Pharmacokinetic and Drug-Interaction Study of Dasatinib in Patients With Advanced Solid Tumors
(
1919 Johnson FM, Agrawal S, Burris H, Rosen L, Dhillon N, Hong D, et al. Phase 1 pharmacokinetic and drug-interaction study of Dasatinib in patients with advanced solid tumors. Cancer [Internet]. 2010 [cited 2016 Oct 16]; 116:1582-91. Available from: http://onlinelibrary.wiley.com/doi/10.1002/cncr.24927/pdf
http://onlinelibrary.wiley.com/doi/10.10...
)
|
United States, 2010 |
Clinical trial 29 patients with advanced solid tumors |
- Dasatinib: QTc interval prolongation on the electrocardiogram (3.5%). |
A Prospective Randomized Trial of Doxorubicin Versus ldarubicin in the Treatment of Advanced Breast Cancer
(
2020 Lopez M, Contegiacomo A, Vici P, Ioio CD, Lauro L, Pagliarulo C, et al. A prospective randomized trial of Doxorubicin versus ldarubicin in the treatment of advanced breast cancer. Cancer [Internet]. 1989 [cited 2016 Oct 16]; 64:2431-6. Available from: http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19891215)64:12%3C2431::AID-CNCR2820641206%3E3.0.CO;2-1/pdf
http://onlinelibrary.wiley.com/doi/10.10...
)
|
United States, 1989 |
Clinical trial 76 patients with advanced breast cancer |
- Idarubicin: reduced left ventricular ejection fraction (5.8%) |
Phase I Clinical Trial of Orally Administered 4-Demethoxydaunorubicin (Idarubicin) with Pharmacokinetic and in Vitro Drug Sensitivity Testing in Children with Refractory Leukemia
(
2121 Pui C, Graaf SSN, Dow LW, Rodman JH, Evans WE, Alpert BS, et al. Phase I clinical trial of orally administered 4- Demethoxydaunorubicin (Idarubicin ) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia. Cancer Res [Internet]. 1988 [cited 2016 Oct 16]; 48:5348-52. Available from: http://cancerres.aacrjournals.org/content/48/18/5348.full-text.pdf
http://cancerres.aacrjournals.org/conten...
)
|
United States, 1988 |
Clinical trial 15 children with acute refractory leukemia |
- Idarubicin: reduced left ventricular ejection fraction (6.6%) and of fractional shortening (40%). |
Capecitabine, an Oral Fluoropyrimidine Carbamate With Substantial Activity in Advanced Colorectal Cancer: Results of a Randomized Phase II Study
(
2222 Cutsem EV, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, et al, Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase ii study. J Clin Oncol [Internet]. 2000 Mar [cited 2016 Oct 16]; 18(6): 1337-45. Available from: https://www.ncbi.nlm.nih.gov/pubmed/10715306
https://www.ncbi.nlm.nih.gov/pubmed/1071...
)
|
United States, 2000 |
Clinical trial 109 patients with advanced colorectal cancer |
- Capecitabine: Angina (1.8%), atrial fibrillation (0.9%) and chest pain (2.7%). |
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate
(
2424 Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol [Internet]. 2008 [cited 2016 Oct 16]; 19:1613-8. Available from: http://annonc.oxfordjournals.org/content/19/9/1613.full.pdf+html
http://annonc.oxfordjournals.org/content...
)
|
England, 2008 |
Cohort 48 patients with renal cell cancer or gastrointestinal stromal tumor |
- Sunitinib: ventricular dysfunction with the reduced left ventricular ejection fraction (12.5%) and cardiogenic shock (2%). |
Cardiotoxicity Associated with the Tyrosine Kinase Inhibitor Sunitinib
(
2525 Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with the Tyrosine Kinase Inhibitor Sunitinib. Lancet [Internet]. 2007 [cited 2016 Oct 16]; 370(9604):2011-9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2643085/pdf/nihms37146.pdf
https://www.ncbi.nlm.nih.gov/pmc/article...
)
|
England, 2007 |
Cohort 75 patients with imatinib resistant gastrointestinal stromal tumor |
- Sunitinib: congestive heart failure (8%), reduced left ventricular ejection fraction (28%), rise in troponin (18%) and death after myocardial infarction (1.3%). |
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis
(
2626 Lorenzo G, Autorino R, Bruni G, Carteni G, Ricevuto E, Tudini M, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol [Internet]. 2009 [cited 2016 Oct 16]; 20:1535-42. Available from: http://annonc.oxfordjournals.org/content/20/9/1535.full.pdf+html
http://annonc.oxfordjournals.org/content...
)
|
England, 2009 |
Cohort 175 patients with metastatic renal cell carcinoma |
- Sunitinib: reduced left ventricular ejection fraction (18.9%) and congestive heart failure (6.9%). |
QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors
(
2727 Ghatalia P, Je Y, Kaymakcalan MD, Sonpavde G, Choueiri TK. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. British J Cancer [Internet]. 2015 [cited 2016 Oct 16]; 112(2):296-305. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453446/pdf/bjc2014564a.pdf
https://www.ncbi.nlm.nih.gov/pmc/article...
)
|
England, 2015 |
Metanalysis 6548 patients with hepatocellular carcinoma, soft tissue sarcoma, renal cell carcinoma, colorectal, prostate, pancreatic, breast, thyroid, lung or gallbladder cancer |
- Tyrosine kinase inhibitors in general: changes in electrocardiogram (4.4%, RR= 66, CI= 95% and p=0.001 in relation to other antineoplastic agents). - Axitinib: ventricular tachycardia (0.33%). - Capecitabine: Atrial fibrillation (0.93%). - Vandetanib: Atrial fibrillation (0.56%), ventricular tachycardia (1.37%) and cardiac arrest (0.15%). - Pazopanib: atrial fibrillation (0.37%) and cardiac arrest (0.34%). |
Comprehensive side-eff ect profi le of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial
(
2929 The Arimidex, Tamoxifen, Alone or in combination Trialists' Group. Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol [Internet]. 2006 [cited 2016 Oct 16]; 7:633-43. Available from: http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(06)70767-7.pdf
http://www.thelancet.com/pdfs/journals/l...
)
|
England, 2006 |
Clinical trial 6241 women after menopause with breast cancer |
- Anastrozole: angina, myocardial infarction, myocardial ischemia and coronary artery disease (2%). - Tamoxifeno: Angina, myocardial ischemia and coronary artery disease (2%) and myocardial infarction (1%). |
Activity of 4 Demethoxydaunorubicin by the Oral Route in Advanced Breast Cancer
(
3030 Martoni A, Pacciarini MA, Pannuti F. Activity of 4-Demethoxydaunorubicin by the Oral Route in Advanced Breast Cancer. Eur J Cancer Clin Oncol [Internet]. 1985 Jul [cited 2016 Oct 16]; 21(7): 803-6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/3862582
https://www.ncbi.nlm.nih.gov/pubmed/3862...
)
|
|
Clinical trial 29 patients with advanced breast cancer |
- Idarrubicina: Changes in electrocardiogram (6.8%) and reduced left ventricular ejection fraction (3.4%). |
A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors
(
3131 Heath EI, Infante J, Lewis LD, Luu T, Stephenson J, Tan AR, et al. A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors. Cancer Chemother Pharmacol [Internet]. 2013 [cited 2016 Oct 16]; 71(3):565-73. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899892/pdf/nihms-516601.pdf
https://www.ncbi.nlm.nih.gov/pmc/article...
)
|
Germany, 2013 |
Clinical trial95 patients with advanced solid tumors |
- Pazopanib: decreased heart rate (mean= 9.9 bpm), prolongation of 4.4 ms in the QTc interval (90 % CI: -2.4, 11.2), compared to placebo. |
Clinical cardiac safety profile of nilotinib
(
3232 Kim TD, Coutre P, Schwarz M, Grille P, Levitin M, Fateh-Moghadam S, et al. Clinical cardiac safety profile of nilotinib. Haematol [Internet]. 2012 [cited 2016 Oct 16]; 97(6):883-9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366654/pdf/0970883.pdf
https://www.ncbi.nlm.nih.gov/pmc/article...
)
|
Italy, 2012 |
Cohort 81 patients previously treated with nilotinib |
- Nilotinib: Myocardial infarction (2.4%), acute coronary syndrome (7.4%), atrial fibrillation (1.2%), angina (1.2%) and changes in electrocardiogram (20%). |
Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment
(
3333 Elenkova A, Shabani R, Kalinov K, Zacharieva S. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. European J Endocrinol [Internet]. 2012 [cited 2016 Oct 16]; 167(1):17-25. Available from: http://www.eje-online.org/content/167/1/17.full.pdf+html
http://www.eje-online.org/content/167/1/...
)
|
Norway, 2012 |
Case-control 334 patients with prolactinoma |
- Cabergoline: Asymptomatic pericardial effusion (0.9%) and risk of cardiac fibrosis (OR=2.27, p= 0.016). - Bromocriptine: Asymptomatic pericardial effusion (1.8%) and risk of cardiac fibrosis (OR=2.66, p= 0.014). |